Scalper1 News
The anti-PD-1 class of cancer fighters continued to shine at a major medical meeting Monday, though analysts continued to debate just how wide a population they can eventually treat. On Monday morning at the American Association for Cancer Research (AACR) meeting in Philadelphia, Bristol-Myers Squibb (BMY) reported positive midstage trial results for the combo of its new anti-PD-1 Opdivo with its older drug Yervoy in treated advanced melanoma. The Scalper1 News
Scalper1 News